December 20, 2024- Roche announced that it has received CE mark approval for its cobas® Mass Spec solution including the cobas® i 601 analyzer and the first Ionify® reagent pack of four assays for steroid hormones. The approval is the first milestone in the global launch of the cobas Mass Spec solution, using in-house innovation to bring automated, integrated and standardized clinical mass spectrometry testing to routine laboratories worldwide. Following launch, the cobas Mass Spec solution will roll out a menu offering of more than 60 analytes for testing of steroid hormones, vitamin D metabolites, immunosuppressant drugs (ISD), therapeutic drug monitoring (TDM) and drugs of abuse testing (DAT).